Evidence map›Paper›PMID 29654270›Full record

ArticleLeukemia2018

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Laura N Eadie, Timothy P Hughes, Deborah L White

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Laura N EadieCancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
Timothy P HughesCancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
Deborah L WhiteCancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. deborah.white@sahmri.com.
South Australian Health and Medical Research Institute · AUSouth Australia Pathology · AUUniversity of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsATP Binding Cassette Transporter, Subfamily BHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveOctamer Transcription Factor-1PrazosinProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesRNA, MessengerABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BImatinib MesylatenilotinibOctamer Transcription Factor-1PrazosinProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesRNA, Messenger

Identifiers

PMID29654270
OpenAlexW2793127628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.